This compound is primarily utilized in the development of targeted cancer therapies, particularly as an inhibitor of specific tyrosine kinases involved in tumor growth and proliferation. Its structure allows it to bind selectively to kinase domains, disrupting signaling pathways that promote cancer cell survival. Researchers explore its potential in treating cancers such as non-small cell lung cancer and breast cancer, where aberrant kinase activity is often observed. Additionally, it is studied for its efficacy in overcoming resistance to existing kinase inhibitors, offering a promising avenue for improved therapeutic outcomes. Its phosphonate group enhances cellular uptake and stability, making it a valuable candidate for further drug development and clinical trials.